statnews.com·Jun 25, 2026
At the BIO 2026 conference in San Diego, biotech executives discussed challenges posed by China's growing influence in drug development, the impact of U.S. political dynamics on drug pricing, and strategies to leverage artificial intelligence for competitive advantage in the industry.
The most valuable insight from the BIO 2026 conference for a professional in healthtech and biotech is the industry's focus on leveraging artificial intelligence for competitive advantage amidst rising costs. Executives are actively strategizing around AI's integration into drug discovery and development, suggesting a potential area for investment or partnership opportunities in AI-driven biotech solutions to maintain a competitive edge in the U.S. market.